BiomX Inc. (PHGE) Form 10-Q — May 20, 2026
BiomX Inc. (PHGE) reported a net loss of $19.1 million for the first quarter of 2026, driven by non-cash warrant revaluation charges and a day-one loss on a private placement, while explicitly stating substantial doubt about its ability to continue as a going concern. The company has only $1.2 million in cash and an accumulated deficit of $236 million, with management estimating funds are sufficient for only several more months of operations. The company has pivoted from its legacy phage therapy business to defense and security technology, completing acquisitions of Dr.
Key figures
- Total Debt
- 4132000
- Total Assets
- 3251000
- Cash Position
- 1168000
- Shares Outstanding
- 10146516
- Operating loss q1
- 1296000
- Accumulated deficit
- 236036000
- Reverse split ratio
- 1:19
- Dfsl acquisition cash
- 750000
- Dfsl acquisition note
- 3000000
- Mandragola credit line
- 2000000
- Zoronet acquisition note
- 1250000
- Warrant liability fair value
- 1685000
Price after filing
Close on the filing date to close N calendar days later (from $0.60). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.